The federal Food and Drug Administration (FDA) says it managed to avert a “crisis” for kids with cancer by preventing a looming shortage of the lifesaving drug methotrexate, a mainstay of treatment for a type of childhood leukemia.
The shortage is the latest in a series of serious shortages of cancer medications and other drugs that have frustrated doctors and patients over the past year and a half.
Only a few days ago, cancer specialists had predicted they could run out of methotrexate by the end of next week, according to Dr. Michael Link, a pediatric oncologist who is president of the American Society of Clinical Oncology. The shortfall arose when 1 of the 4 U.S. makers of methotrexate, Ohio-based Ben Venue Laboratories, shut down production late last year because of “manufacturing and quality concerns,” FDA spokeswoman Shelly Burgess said.
Read the full story at: http://tinyurl.com/6vbfmqd
Additional media coverage available at Kaiser Health News: http://tinyurl.com/7d5396h
Sources: Gannett News Service, Chicago Sun-Times, Kaiser Health News
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen